Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma

Abstract: Early results of a prospective phase 2 clinical trial of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance in high-risk smoldering myeloma showed promising results that were previously published. Here, we provide novel insights into the genetic landscape of...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sham Mailankody, Dickran Kazandjian, Neha Korde, Mark Roschewski, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mary Kwok, Yong Zhang, Adriana Zingone, Laurence Lamy, Rene Costello, Candis Morrison, Malin Hultcrantz, Austin Christofferson, Megan Washington, Martin Boateng, Seth M. Steinberg, Maryalice Stetler-Stevenson, William D. Figg, Elli Papaemmanuil, Wyndham H. Wilson, Jonathan J. Keats, Ola Landgren
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2017-10-01
coleção:	Blood Advances
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2473952920303360
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!